China\'s NMPA approves Amgen\'s Repatha to reduce cardiovascular event risk httpbit.ly2MwwUWVÂ pharma

China's NMPA approves Amgen's Repatha to reduce cardiovascular event risk http://bit.ly/2MwwUWV  #pharma

13:00 EST 25 Jan 2019 | Pharmafile

China's NMPA approves Amgen's Repatha to reduce cardiovascular event risk http://bit.ly/2MwwUWV  #pharma

More From BioPortfolio on "China's NMPA approves Amgen's Repatha to reduce cardiovascular event risk http://bit.ly/2MwwUWV  #pharma"